QNTM
Quantum BioPharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.66
−1.61%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.69
From 52W high−81.69%
Volume94513.00
Market cap$29.60M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.69
From 52W high
−81.69%
Volume
94513.00
Market cap
$29.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
59.9
MomentumView details →
1D Return
−1.61%
YTD Return
−48.97%
SummaryUpdated Jun 1, 2026
Quantum BioPharma Ltd. (NASDAQ:QNTM) is a Canadian biopharmaceutical company headquartered in Toronto that focuses on developing treatments for challenging neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse disorders. Originally founded as FSD Pharma Inc., the company rebranded to Quantum BioPharma Ltd. in August 2024 to better reflect its strategic focus on biopharmaceutical development. The company operates as a clinical-stage biotech firm with drug candidates in various stages of development, maintaining a dual business model that combines pharmaceutical research with strategic real estate investments.
Similar companies
Latest newsMore news →
Quantum BioPharma Ltd. received FDA clearance to begin clinical trials for a multiple sclerosis treatment.11d agoQuantum BioPharma reached the halfway point in patient enrollment for its pilot MS imaging study with Massachusetts General Hospital, with preliminary PET imaging data showing encouraging signals in acute MS lesions.48d ago